secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001013762-25-002718
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro to present first preclinical data for bispecific HER2 x CD3 T-cell engager at AACR 2025
--------------------------------------------------------------------------------

- Oral presentation of ABP-102/CT-P72 at AACR 2025 in New Drugs on the Horizon session on April 27, 2025.
- ABP-102/CT-P72 is a tetravalent bispecific HER2 x CD3 T-cell engager developed under a strategic partnership with Celltrion.
- Data are under embargo until presentation; no results disclosed.
- Presenter: Adam J. Pelzek, Ph.D., Associate Director at Abpro.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000101376225002718/0001013762-25-002718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000101376225002718/ea023575401-8k_abpro.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-002718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer